Published Paper Details:

Metabolic disorder is related with risk for type 2 diabetes and cardiac disease. According to this review it shows that the fundamental features of the pathophysiology, diagnosis and the treatment of the metabolic disorders of hyperlipidaemia. Due to cause of this metabolic disorder hyperlipidaemia distinguish by hypertriglyceridemia and decreased level of highdensity lipoprotein or good cholesterol. The therapeutic management of the metabolic syndrome, regardless of the control of the bodyweight, BP, hyperglycaemia or overt diabetes mellitus, aims at maintaining optimum plasma lipid levels. Therapeutic goals are likely to those for high-risk situations because of the coexistence of many risk factors. The primary goal in treatment should be achieving an LDL-C level of n LDL-C level of < 100 mg/dL or (<70 mg/dL in cases with established ischemic heart diseases or risk equivalent) A further goal is increasing the HDL-C level to ?40 mg/dL in men or 50 mg/dL in women. A non-HDL-C goal of 130 mg/dL should also be aimed at in cases of hypertriglyceridemia.